New Preclinical Research Presented at AACR 2019 Reveals Unique Anti-Cancer Mechanism of Action Underscoring IMV’s Immunotherapy Program
“The new preclinical data shared at this year’s AACR Annual Meeting
provides greater insight into the unique mechanism of our immunotherapy
In the poster titled, T-distributed stochastic neighbor embedding (t-SNE) analysis of tumor infiltrating lymphocytes after treatment with a T cell activating therapy identifies a unique population of recruited CD8+ T cells and novel options for combination immunotherapy, IMV researchers used specialized data analytics to examine how DPX-based agents, when combined with cyclophosphamide (CPA), induced T cells to infiltrate tumors and attack cancerous cells. The study closely examined the types of immune cell responses and how and why they were able to affect disease.
The data indicated that this approach stimulated the infiltration of a broad base of immune cells into tumors, including T cells, NK cells, and macrophages. The specific T cell population that moved into tumors could be grouped based on the co-expression of different checkpoint molecules such as PD-1 and Tim-3. However, those stimulated to infiltrate tumors generally did not express CTLA-4 (a protein found on T cells that inhibits the immune response).
Researchers also found that combining DPX/CPA treatments with a CTLA-4-blocking antibody increased efficacy in controlling tumor growth in the animal models. The data suggested that this result was due to the antibodies acting on T cells present in the tumors, rather than those induced by treatment. This finding contrasts previously published studies with anti-PD-1 combinations in which treatment directly enhanced DPX-induced T cell responses.
“We believe there is a need for more targeted immunotherapy approaches and this work is another important step for us toward achieving this goal,” said Frederic Ors, Chief Executive Officer, at IMV. “This is a new frontier in immuno-oncology drug development, and I’m proud of the work our team has done and the potential it represents to, ultimately, improve treatments for patients.”
IMV’s current clinical program includes multiple phase 2 studies assessing the safety and efficacy of its lead candidate, DPX-Survivac, in combination with mCPA and Merck’s checkpoint inhibitor, Keytruda®.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses activities or
developments that we expect to occur in the future is forward-looking
information. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. In the press
release, such forward-looking statements include, but are not limited
to, statements regarding the FDA potentially granting accelerated
regulatory approval of DPX-Survivac. However, they should not be
regarded as a representation that any of the plans will be achieved.
Actual results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials and the
receipt and timely receipt of all regulatory approvals.
Andrea Cohen, Sam Brown Inc.
O: (917) 209-7163 E: firstname.lastname@example.org
Marc Jasmin, IMV Senior Director, Investor Relations and Communications
O: (902) 492-1819 ext: 1042
M: (514) 917-9481 E: email@example.com